Ironwood Pharma (IRWD) Misses Q1 EPS by 10c ; Offers Guidance

Ironwood Pharma (NASDAQ: IRWD) reported Q1 EPS of ($0.14), $0.10 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $41.14 million versus the consensus estimate of $67.36 million.

GUIDANCE:

Ironwood Pharma sees FY2025 revenue of $260-290 million, versus the consensus of $286.8 million.

For earnings history and earnings-related data on Ironwood Pharma (IRWD) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• Gyre Therapeutics (GYRE) files for 30.22M share offering by selling stockholders
• Keurig Dr Pepper coffee chief to depart ahead of planned split